SCHEMBL10133145

SCHEMBL10133145

CN1CCN(c2ccc(COc3ccc(CNC(=O)Cc4ccccc4)nc3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.53
NPC1 O15118 1/20 0.53
MAPT P10636 4/20 0.50
MAPK1 P28482 2/20 0.50
KMT2A Q03164 2/20 0.50
USP2 O75604 1/20 0.50
ESR2 Q92731 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
FLT3 P36888 3/20 0.48
KIT P10721 2/20 0.48
ABL1 P00519 1/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
LYN P07948 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
BCR P11274 1/20 0.47
SRC P12931 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133151 0.94 RAB9A (0.53) RAB9ANPC1MAPTMAPK1KMT2A
SCHEMBL10133154 0.90 NPC1 (0.54) RAB9ANPC1MAPTMAPK1KMT2A
SCHEMBL10133148 0.88 RAB9A (0.58) RAB9ANPC1MAPTMAPK1KMT2A
SCHEMBL10133152 0.88 RAB9A (0.58) RAB9ANPC1MAPTMAPK1KMT2A
SCHEMBL10133168 0.85 POLB (0.60) RAB9ANPC1MAPTKMT2AABL1
SCHEMBL10133125 0.81 TUBB4A (0.70) MAPTABL1TUBB4ATUBBLYN
SCHEMBL10133156 0.81 NPC1 (0.62) RAB9ANPC1MAPTKMT2AHTR6
SCHEMBL10133128 0.78 TUBB4A (0.70) MAPTABL1TUBB4ATUBBLYN
SCHEMBL10133171 0.77 POLB (0.59) RAB9ANPC1MAPTKMT2ASRC
SCHEMBL23121600 0.76 P4HTM (0.55) KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 RAB9A 2804/4885NPC1 3447/4885MAPT 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.